Approximately 60% to 70% of patients aged 18 to 65 years will achieve a complete remission, but just 30.5% of these patients ...

On 15 August 2025, Artiva Biotherapeutics Inc. announced a phase 2a study to evaluate the safety and efficacy of AlloNK®, an allogeneic cord blood-derived NK cell therapy, in combination with ...

A research team led by Prof. Wang Yi and Wei Haiming from the University of Science and Technology of China (USTC), in ...

Researchers mapped immune cells from centenarians, their offspring, and younger controls across three cohorts using multi-omics single-cell profiling. They found that centenarians retain leaner helper ...

About NKGen Biotech NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is ...

Imminent launch of grant-funded clinical trial in graft-versus-host disease (GVHD)Advancing clinical program in severe pulmonary inflammatory ...

Researchers at Karolinska Institutet have uncovered a unique ability of a special subtype of natural killer cells in the immune system, called adaptive NK cells, to remember ovarian tumours and ...

A comprehensive analysis published in Reserch illuminates how cancer cells hijack immune checkpoints on natural killer (NK) cells to disable the body’s frontline defense system. The study details: ...

"These genetically modified NK cells offer a great treatment opportunity for patients with solid tumors that are currently resistant to immunotherapy ", explains Dr. Clara Montagut, researcher at the ...

LONDON, GREATER LONDON, UNITED KINGDOM, September 10, 2025 /EINPresswire.com/ -- What Is The Expected Cagr For The Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Through 2025?